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Follow-upObjective: Neopterin is a sensitive marker for cell-mediated immune response. Because of
this, the neopterin levels of body fluids show cell-mediated immune response in different
infectious diseases which involve T cells and macrophages.
The aim of this study was to determine the clinical importance of neopterin levels in
patients with tuberculosis and compare with those levels of healthy subjects.
Methods: Seventy patients with tuberculosis (46 newly diagnosed cases, 15 relapse cases,
and 9 multidrug-resistant tuberculosis cases) and 18 healthy adult individuals were
included in the study. Neopterin concentrations were measured by the ELISA method
according to the protocol of the manufacturer. Chi-square test was used in statistical anal-
ysis; p 6 0.05 was considered statistically significant.
Results: Serum mean neopterin levels were 23.74 ± 21.8 nmol/L (median: 18.3) in newly
diagnosed patients with pulmonary tuberculosis; 28.69 ± 21.2 nmol/L (median: 21.2) in
relapse patients and 31.28 ± 14 nmol/L (median: 25.4) in multidrug-resistant tuberculosis
cases, respectively. Serum mean neopterin levels were 4.03 ± 5.12 nmol/L (median: 5.1) in
healthy subjects. The serum neopterin levels were found to be significantly higher in
patients with tuberculosis than the control group.
There was a statistically significant correlation between neopterin positivity (neopterin
level P10 nmol/L was accepted to be positive) and clinical symptoms of hemoptysis and
weight loss. Besides statistically significant correlations between neopterin positivity and
hemoglobin level, sedimentation rate, mean leukocyte count and radiological involvement
(localized or diffuse) were determined.
Conclusion: Serum neopterin levels can be used as a helper laboratory finding for the diag-
nosis of patients with tuberculosis. For this aim, further controlled studies are needed.
 2014 Asian-African Society for Mycobacteriology. Published by Elsevier Ltd. All rights
reserved.oji Klinig˘i,
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Introduction
Neopterin is a pyrazino-pyrimidine compound belonging to
the pteridine class, which is only produced by living cells
[1]. Neopterin is produced from guanosine triphosphate by
stimulated macrophages under the effect of lymphocyte-
originated gamma interferon. Neopterin is an important
marker which plays a key role in the interaction of monocyte/
macrophage activation [2]. Neopterin was demonstrated to
be a sensitive marker of cell-mediated immune reactions;
therefore, the identification of neopterin levels in various
body fluids has diagnostic significance in numerous diseases
including the diseases of T-lymphocytes andmacrophages [1,3].
Mycobacterium tuberculosis (MTB) is an intercellular patho-
gen with the ability to live for a long time in macrophages.
Tuberculosis (TB) bacilli that are phagocyted by macrophages
cannot be killed by polymorphonuclear leukocytes. Neop-
terin is released by the stimulation of intracellular viruses
and bacteria, such as TB, and provides information about
the status of cell-mediated immunity [1,4]. The aim of this
study is to determine the clinical importance of serum neop-
terin levels and compare them with those levels of a control
group.
Materials and methods
This study was performed in cooperation with the Ankara
Training and Research Hospital and Atatu¨rk Chest Diseases
and Thoracic Surgery Training and Research Hospital, Chest
Diseases Department.
Diagnosis of pulmonary tuberculosis (PTB) was made with
clinical symptoms, acid fast bacillus (AFB) smear positivity in
sputummicroscopy, culture positivity for MTB, and radiologic
findings.
Symptom control among the healthy individuals was elim-
inated with physical examination and PA chest radiography.
The patients were comprised of three groups, including
newly diagnosed, relapse and multidrug-resistant (MDR) pa-
tients with TB.
Newly diagnosed patients with TB: These are the patients
that have not taken TB treatment before or the patients that
have taken TB treatment less than one month.
Relapse case of TB: The patient was accepted as a relapse if
the patient who had been diagnosed with TB and who had
completed the treatment successfully was diagnosed with
TB again; in other words, the presence of AFB smear positivity
in sputum microscopy.
Multidrug-resistant tuberculosis (MDR-TB) cases: Resis-
tance of a patient to both isoniazid and rifampicine, which
are used in the treatment of TB.
Blood samples were taken from all TB patients before the
diagnosis and before beginning the treatment.
After separation, the serum samples were stored at 40 C
in a deep freezer. Neopterin levels were determined by ELISA
method in accordance with the instructions of the producing
company (IBL Medical, Turkey). Data were recorded using
SPSS software. Chi-square test was used for statistical evalu-
ation. Patients were evaluated in three groups, including new-
ly diagnosed (Group 1), relapse (Group 2) and MDR patients(Group 3), respectively. The associations of the groups with
ysis, chest pain, fever, andweight loss), duration of symptoms
and degree of radiological involvement (diffuse cavitary, local-
ized cavitary) were statistically evaluated.
Cases with neopterin levels P10 nmol/L and <10 nmol/L
were determined as positive or negative, respectively. Dura-
tion of symptoms between patients with positive and nega-
tive Neopterin symptoms (coughing, sputum, dyspnea,
hemoptysis, and chest pain), duration of symptoms and labo-
ratory findings (hemoglobin levels, leukocyte count and sedi-
mentation rate) were also compared statistically; p levels
60.05 were accepted to be significant.
Informed consent forms were received from the patients,
and approval of the Atatu¨rk Chest Diseases and Thoracic
Surgery Training and Research Hospital Ethic Committee
was obtained for the study.
Results
A total of 70 inpatients from Atatu¨rk Chest Diseases and Tho-
racic Surgery Training and Research Hospital, Chest Diseases
Department, including 46 newly diagnosed patients with TB
(Group 1), 15 relapse patients (Group 2), 9 patients with
MDR-TB patients (Group 3) and a total of 18 healthy subjects
as the control group were enrolled in the study.
Time to onset of the symptoms was 62 ± 39 days in Group
1, 17 ± 61 days in Group 2, and 58 ± 13 days in Group 3. There
was a statistically significant difference between the Groups 1
and 2 (p < 0.01) regarding the time to onset of the symptoms,
but not between the Groups 1 and 3 (p > 0.01).
Neopterin levels were significantly higher in the patient
groups versus the control group (p < 0.05). Results are pre-
sented in Table 1.
Neopterin levels were positive (neopterin level P10 nmol/
L) in 45 of 70 (64.3%) patients with TB and 4 of 18 (22%) in
the control group. Neopterin positive patients (34 males, 11
females) and neopterin negative patients (16 males and 9 fe-
males) did not differ significantly in terms of gender
(p > 0.05). Comparison of neopterin levels between the patient
groups did not reveal any difference (p > 0.05).
The associations of neopterin levels with clinical symp-
toms (for example, time to onset of the symptoms, sputum
formation and dyspnea, etc.) and laboratory findings (for
example, existence of cavitation, involvement degree of the
lungs, microscopic gradient [from 1+ to 4+ positive], sedimen-
tation rates, etc.) were statistically compared between the
groups. Results are shown in Table 2.
Discussion
Detection of neopterin concentrations in body fluids provides
information about cell-mediated immune response. Neop-
terin is a biologically stabilized molecule, thus the messages
generated during the immune responses can be detected eas-
ily. It is widely used in the follow-up of HIV infection. Neop-
terin is produced by macrophages as a response to
interferon gamma stimulation, and neopterin concentrations
show cellular immune activation [2–5].
Table 2 – The associations of neopterin levels with clinical symptoms and laboratory findings.
Clinical symptoms Neopterin positive group (n:45) Neopterin negative group (n:25) p value
Onset of the symptoms 34.48 days 33,02 days 0.772
Sputum formation and dyspnea 22/45 (49%) 6/25 (24%) 0.169
Hemoptysis 43/45 (95.5%) 17/25 (68%) 0.034*
Chest pain, night sweats, cough and fever 6/45 (13%) 2/25 (8%) p > 0.05
Weight loss 32/45 (71.2%) 8/25 (32%) 0.000*
Laboratory findings
Radiological involvement
(localized or diffuse involvement)
24/45 (53%) 5/25 (%20) 0.018*
Cavity formation 18/45 (40%) 10/25 (40) 0.671
Microscopic gradient (mean rank) 35.2 31.6 0.444
Mean Hb levels (gr/dl) 12.27 ± 1.8 13.38 ± 0.8 0.001*
Mean sedimentation rate (mm/h) 70.04 ± 18.6 57.52 ± 2 0.018*
Mean leukocyte count (mm3) 37.9 25.9 0.018*
* p value shown statistically significant.
Table 1 – Neopterin levels of newly diagnosed, relapse and MDR-TB patients and the control group.
Groups Number Neopterin levels nmol/L (Mean ± SD*) Median Neopterin positivity (P10 nmol/L)
n (%)
Group 1** 46 23.7 ± 21.8 18,3 24/45 (53)
Group 2*** 15 28.7 ± 21.2 21,2 12/45 (27)
Group 3**** 9 31,3 ± 14 nmol/L 25,4 9/45 (20)
Control group 18 4.0 ± 5.1 5,1 4/18 (22)
Total 88 49/88 (55,7)
SD*: Standard deviation.
Group 1**: Newly diagnosed cases; Group 2***: Relapse cases; Group 3****: Multidrug-resistant tuberculosis (MDR-TB) cases.
* p value shown statistically significant.
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mortality and morbidity in the world. Cell-mediated immu-
nity (macrophage activation and T lymphocyte proliferation)
plays an important role in the pathogenesis of TB. Elevated
neopterin levels are reported in patients with PTB [3–5].
Yu¨ksekol et al. [5] reported that neopterin levels in bron-
choalveolar lavage (BAL), serum and urine samples of patients
with TB were significantly higher than thosewith lung cancer,
pneumonia and the healthy control group. In the same study,
higher neopterin levels were determined in urine samples of
patients with moderately advanced radiological lesions than
those with minimal disease. This study concluded that urine
neopterin levels could reflect the activity of lung TB prior to
the diagnosis of the disease via culture tests, and that these
levels were correlated with radiological involvement.
Immanual et al. [6] reported that serum neopterin levels
are found to be increased prior to the treatment in patients
with HIV-negative TB; they decrease in the first month of
the treatment and return back to the normal levels at the
end of the treatment. In this study the decreased rates were
found to be 11–56% in patients with restricted lesions and
11–45% in patients with diffuse lesions. The increased neop-
terin levels following the treatment were found to be associ-
ated with bacteriologically-confirmed patients who relapsed.
Consequently, they stated that identification of neopterin lev-
els could be a marker which could be used to monitor the re-
sponse rate.Baganha et al. [2] reported that neopterin levels in pleural
fluid were higher in pleurisy patients than in those with lung
cancer.
Chiang et al. [7] reported that neopterin adenosine deam-
inase (ADA) and soluble interleukin receptor (SIL-2R) levels
were significantly higher in the pleural fluid of TB patients
with pleurisy compared with those with malignant effusion.
The same study revealed pleural neopterin levels to be higher
in patients with uremic pleural effusion.
Cok et al. [8] compared neopterin and ADA levels in pa-
tients with TB pleurisy and malignant pleurisy. In this study,
neopterin levels in patients with TB were determined to be
higher than those with malignant pleurisy; however, unlike
ADA, neopterin was concluded not to be a significant marker
in clinical usage.
Mohammed et al. [9] stated that neopterin levels in BAL
fluids could reflect the activity grade in patients with PTB.
In a study performed by Gordeuk et al. [10], in 32 HIV-
positive patients among a total of 49 patients with PTB,
neopterin levels were found to be increased at the initiation
of the treatment and decreased at the end of the treatment.
Neopterin levels and IL-2 concentrations of HIV-positive TB
patients were reported to be higher than HIV-negative
patients.
This study did not reveal a statistically significant differ-
ence between newly diagnosed TB cases, relapse cases and
MDR-TB cases.
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hemoptysis symptoms and between the neopterin positivity.
Also, there was a statistically significant association between
neopterin positivity and weight loss. The rate of weight loss
was higher in patients with positive neopterin levels.
When investigated in terms of laboratory findings, patients
with positive neopterin levels had a higher mean leukocyte
count and mean sedimentation rate while patients with posi-
tive neopterin levels had lower Hb levels comparedwith those
with negative neopterin levels. In addition to these findings,
there was a significant correlation between neopterin positiv-
ity and radiological involvements (localized or diffuse).
Radiological involvement is more common in the patients
with positive neopterin than with the patients with negative
neopterin.
In another study performed by Gu¨ler et al. [11] on 40 newly
diagnosed patients, pretreatment neopterin levels were re-
ported to be higher than normal controls. Moreover, pretreat-
ment neopterin levelswere found to be significantly decreased
in the secondmonth of the treatment. Serum neopterin levels
were higher in diffuse disease compared with the patients
with restricted lesions. The study concluded that neopterin
levels were safe immunologic markers to evaluate the activa-
tion status and treatment response of the TB patients. In this
study, pretreatment neopterin levels in TB patients (newly
diagnosed, relapse andMDR-TB patients) were found to be sig-
nificantly higher than the control group. The results of this
study are concordant with the study of Gu¨ler et al. [11].
Finally, it has been concluded that the neopterin level is a
useful marker in the diagnosis and follow-up of TB. Further
controlled trials are needed to evaluate the effectiveness of
neopterin levels in the follow-up of the disease.
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